

Surrey & North West Sussex Area Prescribing Committee

Policy Statement	Ciclosporin (Ikervis®) eye drops for the treatment of severe keratitis in adult patients with dry eye disease that has not improved despite treatment with artificial tears
Policy No:	PCN 210 -2016
Date of Issue	July 2016
Review Date:	<p><i>No review date will be assigned to any drugs or devices that are subject to a NICE Technology appraisal.</i></p> <p><i>The recommendation made by the APC (formerly PCN) will be reviewed when new published evidence becomes available OR there is new published national guidance e.g. NICE)</i></p>
<p>Recommendations: The PCN recommends Ciclosporin (Ikervis®) eye drops (1mg/ml) as a treatment option in line with NICE TA369. Ciclosporin (Ikervis®) will be considered Blue (with an information sheet) on the traffic light system</p>	
<p>Key Considerations:</p> <ul style="list-style-type: none"> NICE TA369 http://www.nice.org.uk/guidance/ta369/resources/ciclosporin-fortreating-dry-eye-disease-that-has-not-improved-despite-treatment-withartificial-tears-82602737172421 	
Date taken to Area Prescribing Committee	July 2016
Agreed by APC members	21 st July 2016